Published in Epilepsia on December 01, 2011
Long-term outcomes of epilepsy surgery in Sweden: a national prospective and longitudinal study. Neurology (2013) 0.94
Depression and anxiety in people with epilepsy. J Clin Neurol (2014) 0.93
The sociodemographic, clinical and pharmacotherapy characteristics influencing quality of life in patients with epilepsy: A cross-sectional study. J Neurosci Rural Pract (2014) 0.87
The long-term effect of vagus nerve stimulation on quality of life in patients with pharmacoresistant focal epilepsy: the PuLsE (Open Prospective Randomized Long-term Effectiveness) trial. Epilepsia (2014) 0.86
Insomnia and epilepsy: a questionnaire-based study. J Clin Sleep Med (2013) 0.81
Alterations in functional connectivity between the hippocampus and prefrontal cortex as a correlate of depressive symptoms in temporal lobe epilepsy. Epilepsy Behav (2013) 0.81
Meta-analyses of antiepileptic drugs for refractory partial (focal) epilepsy: an observation. Br J Clin Pharmacol (2013) 0.80
Network meta-analyses of antiepileptic drug efficacy and tolerability in drug-resistant focal epilepsies: a clinical perspective. Eur J Clin Pharmacol (2014) 0.79
Mood, anxiety, and incomplete seizure control affect quality of life after epilepsy surgery. Neurology (2014) 0.78
Treatment of epilepsy in daily clinical practice: have outcomes improved over the past 10 years? J Neurol (2013) 0.78
Surgical treatment of epilepsy. Continuum (Minneap Minn) (2013) 0.77
Factors associated with hopelessness in epileptic patients. World J Psychiatry (2014) 0.76
Galanin contributes to monoaminergic dysfunction and to dependent neurobehavioral comorbidities of epilepsy. Exp Neurol (2016) 0.75
2014 Epilepsy Benchmarks Area IV: Limit or Prevent Adverse Consequence of Seizures and Their Treatment Across The Lifespan. Epilepsy Curr (2016) 0.75
Epilepsy: Determinants of quality of life in epilepsy go beyond seizure-related variables. Nat Rev Neurol (2012) 0.75
Epilepsy priorities in Europe: A report of the ILAE-IBE Epilepsy Advocacy Europe Task Force. Epilepsia (2015) 0.75
Characteristics associated with quality of life among people with drug-resistant epilepsy. J Neurol (2017) 0.75
ILAE official report: a practical clinical definition of epilepsy. Epilepsia (2014) 7.12
Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia (2009) 7.03
Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol (2011) 3.93
ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia (2006) 3.69
Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia (2008) 2.74
Antiepileptic drug therapy: does mechanism of action matter? Epilepsy Behav (2011) 2.20
Mutations in DEPDC5 cause familial focal epilepsy with variable foci. Nat Genet (2013) 2.10
Posterior reversible encephalopathy syndrome (PRES) in critically ill obstetric patients. Intensive Care Med (2003) 2.02
Movement disorders in sleep: guidelines for differentiating epileptic from non-epileptic motor phenomena arising from sleep. Sleep Med Rev (2007) 2.00
International consensus classification of hippocampal sclerosis in temporal lobe epilepsy: a Task Force report from the ILAE Commission on Diagnostic Methods. Epilepsia (2013) 1.82
Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol (2003) 1.76
Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol (2009) 1.73
Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia (2013) 1.69
Mutations in mammalian target of rapamycin regulator DEPDC5 cause focal epilepsy with brain malformations. Ann Neurol (2014) 1.62
Clinical significance of rare copy number variations in epilepsy: a case-control survey using microarray-based comparative genomic hybridization. Arch Neurol (2011) 1.61
Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia (2007) 1.56
Hepatitis C virus infection in an endemic area of Southern Italy 14 years later: evidence for a vanishing infection. Dig Liver Dis (2012) 1.55
Vigabatrin and epilepsy: lessons learned. Epilepsia (2007) 1.55
Familial mesial temporal lobe epilepsy (FMTLE) : a clinical and genetic study of 15 Italian families. J Neurol (2007) 1.54
Progressive myoclonic epilepsies: definitive and still undetermined causes. Neurology (2014) 1.52
Posterior reversible encephalopathy syndrome in intensive care medicine. Intensive Care Med (2006) 1.52
Physiologic autonomic arousal heralds motor manifestations of seizures in nocturnal frontal lobe epilepsy: implications for pathophysiology. Sleep Med (2012) 1.51
Prospective randomized double-blind trial of racecadotril compared with loperamide in elderly people with gastroenteritis living in nursing homes. Eur J Clin Pharmacol (2009) 1.50
Genome-wide association analysis of genetic generalized epilepsies implicates susceptibility loci at 1q43, 2p16.1, 2q22.3 and 17q21.32. Hum Mol Genet (2012) 1.48
Pharmacovigilance and drug safety 2011 in Calabria (Italy): Adverse events analysis. J Res Med Sci (2012) 1.47
Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia (2012) 1.45
Acute late-onset encephalopathy after radiotherapy: an unusual life-threatening complication. Neurology (2013) 1.42
Sertraline-induced potentiation of the CYP3A4-dependent neurotoxicity of carbamazepine: an in vitro study. Epilepsia (2015) 1.40
Cardiac function and antiepileptic drug treatment in the elderly: a comparison between lamotrigine and sustained-release carbamazepine. Epilepsia (2009) 1.38
Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: reply to Beyenburg et al., 2009. Epilepsia (2010) 1.37
Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res (2010) 1.35
Identification of an Nav1.1 sodium channel (SCN1A) loss-of-function mutation associated with familial simple febrile seizures. Proc Natl Acad Sci U S A (2005) 1.32
The ketogenic diet: from molecular mechanisms to clinical effects. Epilepsy Res (2006) 1.30
Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis. Epilepsia (2011) 1.27
Autosomal dominant lateral temporal epilepsy: clinical spectrum, new epitempin mutations, and genetic heterogeneity in seven European families. Epilepsia (2003) 1.27
Clinical spectrum and critical care management of Posterior Reversible Encephalopathy Syndrome (PRES). Med Sci Monit (2005) 1.25
Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res (2012) 1.24
Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII). Epilepsy Res (2006) 1.23
An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia (2007) 1.23
Levetiracetam for cerebellar tremor in multiple sclerosis: an open-label pilot tolerability and efficacy study. J Neurol (2006) 1.20
Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol (2003) 1.20
Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res (2008) 1.20
Fetal exposure to GABA-acting antiepileptic drugs generates hippocampal and cortical dysplasias. Epilepsia (2007) 1.19
Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt. Oncogene (2004) 1.17
Add-on phenytoin fails to prevent early seizures after surgery for supratentorial brain tumors: a randomized controlled study. Epilepsia (2002) 1.17
Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy. Epilepsia (2004) 1.16
Adverse effects of atypical antipsychotics in the elderly: a review. Drugs Aging (2006) 1.15
Glutamate metabotropic receptors as targets for drug therapy in epilepsy. Eur J Pharmacol (2003) 1.13
Dramatic response to levetiracetam in post-ischaemic Holmes' tremor. J Neurol Neurosurg Psychiatry (2007) 1.13
Antiepileptic drugs and MTHFR polymorphisms influence hyper-homocysteinemia recurrence in epileptic patients. Epilepsia (2007) 1.13
Comparison of the antiepileptogenic effects of an early long-term treatment with ethosuximide or levetiracetam in a genetic animal model of absence epilepsy. Epilepsia (2009) 1.11
Non-paraneoplastic limbic encephalitis associated with anti-glutamic acid decarboxylase antibodies. J Neuroimmunol (2008) 1.10
Genetic basis for idiosyncratic reactions to antiepileptic drugs. Curr Opin Neurol (2009) 1.10
EURAP: an international registry of antiepileptic drugs and pregnancy. Epilepsia (2004) 1.07
Revisiting phenobarbital for epilepsy. BMJ (2004) 1.07
Frontal cognitive dysfunction in juvenile myoclonic epilepsy. Epilepsia (2007) 1.07
Seizure control and treatment changes in pregnancy: observations from the EURAP epilepsy pregnancy registry. Epilepsia (2013) 1.07
Novel potent anticonvulsant agent containing a tetrahydroisoquinoline skeleton. J Med Chem (2006) 1.06
Epilepsy after head injury. Curr Opin Neurol (2004) 1.06
Autosomal recessive epilepsy associated with contactin 2 mutation is different from familial cortical tremor, myoclonus and epilepsy. Brain (2013) 1.06
Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res (2004) 1.05
Antiepileptic drug selection for people with HIV/AIDS: evidence-based guidelines from the ILAE and AAN. Epilepsia (2012) 1.04
The cAMP-HMGA1-RBP4 system: a novel biochemical pathway for modulating glucose homeostasis. BMC Biol (2009) 1.04
Obstructive sleep apnea in a clinical series of adult epilepsy patients: frequency and features of the comorbidity. Epilepsia (2003) 1.04
Autosomal dominant lateral temporal epilepsy: absence of mutations in ADAM22 and Kv1 channel genes encoding LGI1-associated proteins. Epilepsy Res (2008) 1.04
Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells. Biochem Pharmacol (2007) 1.03
Mast cell positivity to tryptase correlates with metastatic lymph nodes in gastrointestinal cancer patients treated surgically. Oncology (2013) 1.03
Clinical and genetic findings in 26 Italian patients with Lafora disease. Epilepsia (2006) 1.03
Hypericum perforatum: pharmacokinetic, mechanism of action, tolerability, and clinical drug-drug interactions. Phytother Res (2013) 1.03
Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-α receptor activation in a genetic model of absence epilepsy. Neuropharmacology (2012) 1.03
Genetic investigations on 8 patients affected by ring 20 chromosome syndrome. BMC Med Genet (2010) 1.02
Anticonvulsant effects of carbenoxolone in genetically epilepsy prone rats (GEPRs). Neuropharmacology (2004) 1.01
Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. Epilepsy Res (2003) 1.01
Withdrawal of antiepileptic drugs: guidelines of the Italian League Against Epilepsy. Epilepsia (2013) 1.01
Isolation and growth of smooth muscle-like cells derived from tuberous sclerosis complex-2 human renal angiomyolipoma: epidermal growth factor is the required growth factor. Am J Pathol (2005) 1.00
Hepatotoxicity induced by methimazole in a previously healthy patient. Curr Drug Saf (2009) 0.99
Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy. Epilepsia (2010) 0.99
Excessive daytime sleepiness and subjective sleep quality in patients with nocturnal frontal lobe epilepsy: a case-control study. Epilepsia (2006) 0.98
Unexpected gamma glutamyltransferase rise increase during levetiracetam monotherapy. Epileptic Disord (2010) 0.97
New and forthcoming anti-epileptic drugs. Curr Opin Neurol (2011) 0.97
Depression and Anxiety in Patients with Epilepsy. Epilepsy Behav (2001) 0.97
Interactions among Low Dose of Methotrexate and Drugs Used in the Treatment of Rheumatoid Arthritis. Adv Pharmacol Sci (2013) 0.96
Antiabsence effects of carbenoxolone in two genetic animal models of absence epilepsy (WAG/Rij rats and lh/lh mice). Neuropharmacology (2005) 0.96
6q terminal deletion syndrome associated with a distinctive EEG and clinical pattern: a report of five cases. Epilepsia (2006) 0.96
The mTOR signaling pathway in the brain: focus on epilepsy and epileptogenesis. Mol Neurobiol (2012) 0.95
Clinical phenotype and molecular characterization of 6q terminal deletion syndrome: Five new cases. Am J Med Genet A (2006) 0.95
Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia (2002) 0.95
Genome-wide linkage meta-analysis identifies susceptibility loci at 2q34 and 13q31.3 for genetic generalized epilepsies. Epilepsia (2012) 0.94
Levetiracetam in patients with cortical myoclonus: a clinical and electrophysiological study. Mov Disord (2005) 0.94
Treatment of epilepsy in developing countries. BMJ (2007) 0.94
Development of new treatment approaches for epilepsy: unmet needs and opportunities. Epilepsia (2013) 0.94